Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CBL dec exp |
| Therapy | Erlotinib + Gemcitabine |
| Indication/Tumor Type | pancreatic ductal carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CBL dec exp | pancreatic ductal carcinoma | predicted - sensitive | Erlotinib + Gemcitabine | Preclinical - Cell line xenograft | Emerging | In a preclinical study, addition of Tarceva (erlotinib) overcame Gemzar (gemcitabine)-resistance in pancreatic ductal carcinoma cell lines with reduced Cbl expression via shRNA, resulted in decreased viability in cell culture and reduced tumor growth in cell line xenograft models (PMID: 25348515). | 25348515 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25348515) | Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition. | Full reference... |